Browsing Category


Unmet need for HIV PrEP therapy

Ryan Haumschild, PharmD, MS, MBA: Carl, which groups of eligible patients are most likely to see PrEP therapy in your experience? We heard Frank and Ryan mention one of the drivers of use, of expanding use, but which groups are most…